Results 141 to 150 of about 63,898 (235)

Getting There First With the Best: The Need to Shorten the Prescription Drug Approval Process [PDF]

, 2011
Kassel, Mark A.
core   +1 more source

Rare biochemical & genetic conditions: clues for broader mechanistic insights. [PDF]

Cell Mol Life Sci
Mentis AA, Dalamaga M.
europepmc   +1 more source

Significance of neutrophil activation in reactional lepromatous leprosy: Effects of thalidomide in vivo and in vitro. Activation in adjuvant disease Yahr, M.G., Convit, J., Rodriguez-Ochoa, G., Aranzazu, N., Villalba-Pimentel, L., Ocanto, A., and deGomez, M.: Int. Arch. Allergy Appl. Immunol. 57:317, 1978

, 1979

openalex   +1 more source

First-Line Treatment of Icaritin and Thalidomide in a Patient With Hepatocellular Carcinoma With PR: A Case Report. [PDF]

Cancer Rep (Hoboken)
Jin Z, Zhou F, Wang Z, Li H.
europepmc   +1 more source

Thalidomide induces amenorrhea in patients with lupus disease [PDF]

, 1998
José Ordi, Fina Cortes, Nuria García-Martínez, Montse Mauri, Inés de Torres, M Vilardell   +5 more
openalex   +1 more source

Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma. [PDF]

BMC Cancer
Kang KW, Kim DS, Lee SR, Heo MH, Eom HS, Jung J, Lee JH, Kim SH, Koh Y, Min CK, Lee SS, Lim SN, Yhim HY, Lee MW, Lee JJ, Jung SH, Bang SM, Kim K, Korean Multiple Myeloma Working party [KMMWP].   +18 more
europepmc   +1 more source

Thalidomide augments maturation and T helper 1-inducing capacity of monocyte-derived dendritic cells in vitro. [PDF]

Bioimpacts
Abbaszadeh M, Naseri B, Masoumi J, Baghbani E, Baradaran B, Sadeghi MR.   +5 more
europepmc   +1 more source

Significant response of oral aphthosis to thalidomide treatment

, 1985
H Brodthagen
openalex   +1 more source

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer [PDF]

, 2000
Tim Eisen, Chris Boshoff, Ian Mak, Francisco Sapunar, M Vaughan, L Pyle, Stephen R.D. Johnston, Roger A’Hern, IE Smith, Martin Gore   +9 more
openalex   +1 more source

Outcomes of daratumumab-bortezomib-thalidomide-dexamethasone in treatment-naive systemic AL amyloidosis. [PDF]

Br J Haematol
Khwaja J, Ravichandran S, Cohen O, Foard D, Low M, Martinez-Naharro A, Venneri L, Fontana M, Hawkins PN, Gillmore J, Lachmann HJ, Whelan C, Mahmood S, Wechalekar A.   +13 more
europepmc   +1 more source